[Stem cell mobilization with plerixafor in pediatric solid tumors patients: a single-center study].

BACKGROUND

Autologous peripheral blood stem cell (PBSC) collection can be challenging in pediatric patients with solid tumors following intensive chemotherapy. Plerixafor, a hematopoietic stem cell mobilizing agent, has been increasingly used in such cases; however, reports from Japan remain limited.

METHODS

We conducted a single-center retrospective observational study to assess the efficacy and safety of plerixafor. Eight pediatric patients with solid tumors (nine mobilization attempts) who received plerixafor at our institution between 2015 and 2024 were included in the analysis.

RESULTS

The median CD34-positive cell count collected was 10.8×106/kg. In all cases, the target cell dose required for autologous transplantation was successfully achieved. Adverse events were mild, including transient headache, elevated liver enzymes, and diarrhea. No severe adverse events were observed.

CONCLUSION

Plerixafor was effective and well tolerated in pediatric patients with solid tumors, regardless of disease status (newly diagnosed or relapsed). These findings support its potential as a valuable stem cell mobilization option in pediatric transplant settings in Japan.